Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NMT1 | P30419 | 8/20 | 0.41 |
| ▸ | NMT2 | O60551 | 3/20 | 0.41 |
| ▸ | TLR7 | Q9NYK1 | 6/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | ACSS2 | Q9NR19 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1486668 | 0.94 | TLR7 (0.40) | NMT1NMT2TLR7MEN1HSP90AA1 | |
| SCHEMBL1486550 | 0.87 | NMT1 (0.38) | NMT1NMT2TLR7MEN1HSP90AA1 | |
| SCHEMBL2889187 | 0.85 | TLR7 (0.44) | TLR7 | |
| SCHEMBL5617822 | 0.85 | MAPT (0.34) | NMT1TLR7MEN1KMT2ALMNA | |
| SCHEMBL3865204 | 0.85 | NMT1 (0.45) | NMT1NMT2MEN1HSP90AA1KMT2A | |
| SCHEMBL4541234 | 0.84 | MAPT (0.44) | NMT1NMT2MEN1KMT2AACSS2 | |
| SCHEMBL1486822 | 0.83 | NMT1 (0.42) | NMT1NMT2TLR7MEN1HSP90AA1 | |
| SCHEMBL1486615 | 0.82 | TLR7 (0.45) | TLR7 | |
| SCHEMBL1486756 | 0.82 | NMT1 (0.44) | NMT1NMT2MEN1KMT2AACSS2 | |
| SCHEMBL6104849 | 0.82 | TLR7 (0.40) | TLR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8263594-B2 | Aryloxy and arylalkyleneoxy substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2012-09-11 | — | — | US | disclosed |
| US-20110144099-A1 | ARYLOXY AND ARYLALKYLENEOXY SUBSTITUTED IMIDAZOQUINOLINES | 3M INNOVATIVE PROPERTIES COMPANY | 2011-06-16 | — | — | US | disclosed |
| US-7897597-B2 | Aryloxy and arylalkyleneoxy substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2011-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110144099-A1 | ARYLOXY AND ARYLALKYLENEOXY SUBSTITUTED IMIDAZOQUINOLINES | IL2, IFNG, IRF3 | NMT1 3677/4885NMT2 3204/4885TLR7 42/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.